Translation of nanomedicines from lab to industrial scale synthesis: The case of squalene-adenosine nanoparticles

Archive ouverte

Dormont, Flavio | Rouquette, Marie | Mahatsekake, Clement | Gobeaux, Frédéric | Peramo, Arnaud | Brusini, Romain | Calet, Serge | Testard, Fabienne | Lepetre-Mouelhi, Sinda | Desmaele, Didier | Varna, Mariana | Couvreur, Patrick

Edité par CCSD ; Elsevier -

International audience. A large variety of nanoparticle-based delivery systems have become increasingly important for diagnostic and/or therapeutic applications. Yet, the numerous physical and chemical parameters that influence both the biological and colloidal properties of nanoparticles remain poorly understood. This complicates the ability to reliably produce and deliver well-defined nanocarriers which often leads to inconsistencies, conflicts in the published literature and, ultimately, poor translation to the clinics. A critical issue lies in the challenge of scaling-up nanomaterial synthesis and formulation from the lab to industrial scale while maintaining control over their diverse properties. Studying these phenomena early on in the development of a therapeutic agent often requires partnerships between the public and private sectors which are hard to establish. In this study, through the particular case of squalene-adenosine nanoparticles, we reported on the challenges encountered in the process of scaling-up nanomedicines synthesis. Here, squalene (the carrier) was functiona-lized and conjugated to adenosine (the active drug moiety) at an industrial scale in order to obtain large quantities of biocompatible and biodegradable nanoparticles. After assessing nanoparticle batch-to-batch consistency , we demonstrated that the presence of squalene analogs resulting from industrial scale-up may influence several features such as size, surface charge, protein adsorption, cytotoxicity and crystal structure. These analogs were isolated, characterized by multiple stage mass spectrometry, and their influence on nanoparticle properties further evaluated. We showed that slight variations in the chemical profile of the nanocarrier's constitutive material can have a tremendous impact on the reproducibility of nanoparticle properties. In a context where several generics of approved nanoformulated drugs are set to enter the market in the coming years, characterizing and solving these issues is an important step in the pharmaceutical development of nanomedicines.

Suggestions

Du même auteur

Assessment of Squalene-Adenosine Nanoparticles in Two Rodent Models of Cardiac Ischemia-Reperfusion

Archive ouverte | Brusini, Romain | CCSD

International audience. Reperfusion injuries after a period of cardiac ischemia are known to lead to pathological modifications or even death. Among the different therapeutic options proposed, adenosine, a small mol...

Leu-Enkephalin Lipid Prodrug Nanoparticles: Relationship between Nanoparticles’ Structure, Interaction with Bovine Serum Albumin, and Analgesic Activity

Archive ouverte | Lepetre-Mouelhi, Sinda | CCSD

International audience. Recently, we proposed in a paper a novel nanomedicine approach based on a versatile bioconjugation linkage (amide, diglycolate, or acylal) between the Leu-enkephalin (LENK), an endogenous neu...

Supramolecular organization and biological interaction of the squalenoyl siRNA nanoparticles

Archive ouverte | Caillaud, Marie | CCSD

International audience. Small interfering RNAs (siRNA) are attractive and powerful tools to inhibit the expression of a targeted gene. However, their extreme hydrophilicities combined with a negative charge and shor...

Chargement des enrichissements...